Company news

ImageneBio, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 2, 2026

ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York

September 8, 2026

ImageneBio Reports Inducement Grants under Nasdaq Listing Rule 5635(4)

August 18, 2026

ImageneBio Reports Second Quarter 2026 Financial Results

August 5, 2026

ImageneBio Appoints Matt Robbins as General Counsel

July 7, 2026

ImageneBio to Participate in 2026 Jefferies Global Healthcare Conference in New York

May 27, 2026

ImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program Update

May 7, 2026

ImageneBio Announces $30 Million Private Placement

April 12, 2026

ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 16, 2026

ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

March 10, 2026

ImageneBio to Participate in Leerink Global Healthcare Conference

February 26, 2026

ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

February 9, 2026

ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team

November 11, 2025

ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences

November 6, 2025

Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million

July 25, 2025

Decks